Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Upstream Bio, Inc. (UPB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: UPB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 407.33M USD | Price to earnings Ratio - | 1Y Target Price 56.5 |
Price to earnings Ratio - | 1Y Target Price 56.5 | ||
Volume (30-day avg) 237994 | Beta - | 52 Weeks Range 5.85 - 29.46 | Updated Date 03/15/2025 |
52 Weeks Range 5.85 - 29.46 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Earnings Date
Report Date 2025-03-12 | When - | Estimate - | Actual -0.4065 |
Profitability
Profit Margin - | Operating Margin (TTM) -3112.52% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188616167 | Price to Sales(TTM) 184.56 |
Enterprise Value 188616167 | Price to Sales(TTM) 184.56 | ||
Enterprise Value to Revenue 85.46 | Enterprise Value to EBITDA - | Shares Outstanding 53596600 | Shares Floating 28482306 |
Shares Outstanding 53596600 | Shares Floating 28482306 | ||
Percent Insiders 19.81 | Percent Institutions 85.58 |
Analyst Ratings
Rating 4.5 | Target Price - | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Upstream Bio, Inc.
Company Overview
History and Background
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to address unmet needs in inflammatory and respiratory diseases. Founded in 2022, they are committed to pioneering innovative approaches to treat diseases by targeting the source.
Core Business Areas
- Drug Development: Development of new medicines for respiratory and inflammatory diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Research and Development: Discovering and developing innovative therapies for immunological diseases.
Leadership and Structure
Upstream Bio, Inc.'s leadership team comprises experienced executives in drug development and commercialization. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- UPB-101: UPB-101, Upstream Biou2019s lead product, is a monoclonal antibody that blocks TL1A, a key mediator of inflammation and fibrosis. It is currently in Phase 2 clinical trials for inflammatory bowel disease (IBD) and asthma. Competitors include companies developing similar TL1A inhibitors, such as Prometheus Biosciences (acquired by Merck), Takeda, and Roivant Sciences.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth driven by advancements in drug development technologies and increasing demand for novel therapies. The inflammatory and respiratory disease market is large and competitive.
Positioning
Upstream Bio is positioning itself as a leader in developing TL1A inhibitors, a novel approach for treating inflammatory and fibrotic diseases. Their competitive advantage lies in their focus on a specific target and their experienced management team.
Total Addressable Market (TAM)
The total addressable market for inflammatory and fibrotic disease is estimated to be hundreds of billions of dollars. Upstream Bio is positioned to capture a significant portion of this market with its lead product candidate.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (TL1A)
- Experienced management team
- Strong financial backing
- Promising Phase 2 clinical trial results
Weaknesses
- Single asset company
- Clinical trial risks
- Dependent on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Expansion into additional indications for UPB-101
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
- Development of additional TL1A inhibitors or other novel therapies
Threats
- Clinical trial failures
- Competition from other TL1A inhibitors
- Regulatory hurdles
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- MRK
- TAK
- ROIV
Competitive Landscape
Upstream Bio faces competition from established pharmaceutical companies and other biotechnology companies developing therapies for inflammatory and fibrotic diseases. Their focus on TL1A inhibition provides a potential competitive advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Since its founding in 2022, Upstream Bio, Inc.'s growth has been focused on advancing its lead product candidate through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of UPB-101. Analyst estimates are not readily available for private companies.
Recent Initiatives: Upstream Bio, Inc. recently announced positive topline results from its Phase 1 clinical trial of UPB-101 and has initiated Phase 2 clinical trials for IBD and asthma.
Summary
Upstream Bio is a clinical-stage biopharmaceutical company focused on novel therapies for inflammatory diseases. Its lead product, UPB-101, targets TL1A and is currently in Phase 2 trials. While promising, the company faces clinical trial risks and competition from larger pharmaceutical companies. Successful clinical trial outcomes and potential partnerships are critical for future growth. A strong focus on demonstrating the efficacy and safety of UPB-101 is crucial for long-term success.
Similar Companies
MRK
Merck & Company Inc
MRK
Merck & Company Inc
ROIV
Roivant Sciences Ltd
ROIV
Roivant Sciences Ltd
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Upstream Bio, Inc. website
- Company press releases
- Industry reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. The AI-based rating is for informational purposes only and should not be considered a recommendation to buy or sell stock.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Upstream Bio, Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-10-11 | CEO & Director Dr. E. Rand Sutherland M.D., M.P.H., MPH | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://upstreambio.com |
Full time employees 52 | Website https://upstreambio.com | ||
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.